222 related articles for article (PubMed ID: 33400504)
1. Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.
de la Fuente Revenga M; Shah UH; Nassehi N; Jaster AM; Hemanth P; Sierra S; Dukat M; González-Maeso J
ACS Chem Neurosci; 2021 Mar; 12(5):831-844. PubMed ID: 33400504
[TBL] [Abstract][Full Text] [Related]
2. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT
de la Fuente Revenga M; Jaster AM; McGinn J; Silva G; Saha S; González-Maeso J
ACS Chem Neurosci; 2022 Aug; 13(16):2436-2448. PubMed ID: 35900876
[TBL] [Abstract][Full Text] [Related]
3. Differences across sexes on head-twitch behavior and 5-HT
Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J
Neurosci Lett; 2022 Sep; 788():136836. PubMed ID: 35963476
[TBL] [Abstract][Full Text] [Related]
4. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
5. The selective 5-HT
Jensen AA; Halberstadt AL; Märcher-Rørsted E; Odland AU; Chatha M; Speth N; Liebscher G; Hansen M; Bräuner-Osborne H; Palner M; Andreasen JT; Kristensen JL
Biochem Pharmacol; 2020 Jul; 177():113979. PubMed ID: 32298690
[TBL] [Abstract][Full Text] [Related]
6. Serotonin 2A Receptor (5-HT
Duan W; Cao D; Wang S; Cheng J
Chem Rev; 2024 Jan; 124(1):124-163. PubMed ID: 38033123
[TBL] [Abstract][Full Text] [Related]
7. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT
Pottie E; Dedecker P; Stove CP
Biochem Pharmacol; 2020 Dec; 182():114251. PubMed ID: 32998000
[TBL] [Abstract][Full Text] [Related]
8. Identification of 5-HT
Wallach J; Cao AB; Calkins MM; Heim AJ; Lanham JK; Bonniwell EM; Hennessey JJ; Bock HA; Anderson EI; Sherwood AM; Morris H; de Klein R; Klein AK; Cuccurazzu B; Gamrat J; Fannana T; Zauhar R; Halberstadt AL; McCorvy JD
Nat Commun; 2023 Dec; 14(1):8221. PubMed ID: 38102107
[TBL] [Abstract][Full Text] [Related]
9. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.
Moreno JL; Holloway T; Albizu L; Sealfon SC; González-Maeso J
Neurosci Lett; 2011 Apr; 493(3):76-9. PubMed ID: 21276828
[TBL] [Abstract][Full Text] [Related]
11. Fully automated head-twitch detection system for the study of 5-HT
de la Fuente Revenga M; Shin JM; Vohra HZ; Hideshima KS; Schneck M; Poklis JL; González-Maeso J
Sci Rep; 2019 Oct; 9(1):14247. PubMed ID: 31582824
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists.
Marcher-Rørsted E; Halberstadt AL; Klein AK; Chatha M; Jademyr S; Jensen AA; Kristensen JL
ACS Chem Neurosci; 2020 May; 11(9):1238-1244. PubMed ID: 32212672
[TBL] [Abstract][Full Text] [Related]
13. 5-HT
Schmitz GP; Jain MK; Slocum ST; Roth BL
ACS Chem Neurosci; 2022 Aug; 13(16):2386-2398. PubMed ID: 35894503
[TBL] [Abstract][Full Text] [Related]
14. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
Smith RL; Barrett RJ; Sanders-Bush E
J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
[TBL] [Abstract][Full Text] [Related]
16. Serotonin 2C receptors are also important in head-twitch responses in male mice.
Custodio RJP; Ortiz DM; Lee HJ; Sayson LV; Kim M; Lee YS; Kim KM; Cheong JH; Kim HJ
Psychopharmacology (Berl); 2023 Oct; ():. PubMed ID: 37882810
[TBL] [Abstract][Full Text] [Related]
17. Automated Detection of Psychedelic-Induced Head-Twitch Response in Mice.
Jaster AM; González-Maeso J
Methods Mol Biol; 2023; 2687():65-76. PubMed ID: 37464163
[TBL] [Abstract][Full Text] [Related]
18. Modulation of DOM-Induced Head-Twitch Response by mGluR2 Agonist/Inverse Agonist is Associated with 5-HT
Gao H; Liu X; Xie L; Tan B; Su R
Neurochem Res; 2024 Mar; 49(3):636-648. PubMed ID: 37989895
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB
Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990
[TBL] [Abstract][Full Text] [Related]
20. Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection.
Ung RV; Landry ES; Rouleau P; Lapointe NP; Rouillard C; Guertin PA
Eur J Neurosci; 2008 Dec; 28(11):2231-42. PubMed ID: 19019202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
